2018 Atrial Fibrillation Drug Development- Pipeline Analysis Report

  • ID: 4527586
  • Report
  • 70 pages
  • VPA Research
10 % OFF
until Nov 30th 2018
1 of 4

FEATURED COMPANIES

  • ActoGeniX
  • Daewoong Pharmaceutical
  • Humanetics Corporation
  • Monopar Therapeutics
  • Oragenics
  • Servier Canada Inc
  • MORE
Atrial Fibrillation or AFib is estimated to affect around 30 million worldwide and is currently regarded as an important research area. With increasing aged population (65+) across several countries, Atrial fibrillation is observed to be one of the leading causes of strokes with strong increase in hospitalization rates. Over 30 companies and universities are focusing on developing treatment options for Atrial Fibrillation.

To assist researchers and business development managers, the publisher has come up with a comprehensive report on Atrial Fibrillation pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Atrial Fibrillation pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Atrial Fibrillation pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ActoGeniX
  • Daewoong Pharmaceutical
  • Humanetics Corporation
  • Monopar Therapeutics
  • Oragenics
  • Servier Canada Inc
  • MORE
1.1 List of Figures
1.2 List of Tables

2 Atrial Fibrillation Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Atrial Fibrillation Pipeline Snapshot
2.3 Atrial Fibrillation Pipeline by Phase
2.4 Atrial Fibrillation Pipeline by Company
2.5 Atrial Fibrillation Pipeline by Mechanism of Action

3 Atrial Fibrillation- Company Wise Pipeline Analysis
  • Acesion Pharma Aps
  • Allosteros Therapeutics Inc
  • AnaBios Corporation
  • ARCA biopharma, Inc.
  • AstraZeneca
  • Bayer
  • Boston Pharmaceuticals
  • Bristol-Myers Squibb
  • Dong-A Socio Holdings Co Ltd
  • Edge Therapeutics, Inc
  • Gilead Sciences, Inc.
  • HUYA Bioscience International
  • InCarda Therapeutics, Inc.
  • Johnson & Johnson Pharmaceutical Research & Development
  • Medtronic, Inc
  • Merck & Co
  • NeuroSearch
  • N-Gene Research Laboratories, Inc.
  • Nissan Chemical Industries, Ltd.
  • Novartis Pharmaceuticals
  • Nyken
  • OMEICOS Therapeutics GmbH
  • Ono Pharmaceutical
  • Pierre Fabre
  • Sanofi
  • ST Pharm
  • Syntex Pharmaceuticals International
  • The Geneva Biotech Center SA
  • Verseon
  • Xention
4 Atrial Fibrillation R&D Pipeline Snapshots
  • Drug wise Pipeline Details
  • Therapeutic Candidate Name
  • Originator
  • Co-Developer/ License Partner
  • Orphan Drug Designation
  • Development Phase
  • Mechanism of Action
  • Current Status
  • Ongoing Clinical Trial Details
5 Recent Developments in Atrial Fibrillation Pipeline

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Atrial Fibrillation Pipeline by Phase, H1- 2018
Figure 2: Atrial Fibrillation Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Atrial Fibrillation Pipeline by Mechanism Of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

1.2 List of Tables
Table 1: Atrial Fibrillation Pipeline by Phase, H1- 2018
Table 2: Atrial Fibrillation Pipeline by Companies, H1- 2018
Table 3: Atrial Fibrillation Pipeline by Mechanism Of Action, H1- 2018
Table 4: Acesion Pharma Aps Atrial Fibrillation Pipeline, May 2018
Table 5: Allosteros Therapeutics Inc Atrial Fibrillation Pipeline, May 2018
Table 6: AnaBios Corporation Atrial Fibrillation Pipeline, May 2018
Table 7: ARCA biopharma, Inc. Atrial Fibrillation Pipeline, May 2018
Table 8: AstraZeneca Atrial Fibrillation Pipeline, May 2018
Table 9: Bayer Atrial Fibrillation Pipeline, May 2018
Table 10: Boston Pharmaceuticals Atrial Fibrillation Pipeline, May 2018
Table 11: Bristol-Myers Squibb Atrial Fibrillation Pipeline, May 2018
Table 12: Dong-A Socio Holdings Co Ltd Atrial Fibrillation Pipeline, May 2018
Table 13: Edge Therapeutics, Inc Atrial Fibrillation Pipeline, May 2018
Table 14: Gilead Sciences, Inc. Atrial Fibrillation Pipeline, May 2018
Table 15: HUYA Bioscience International Atrial Fibrillation Pipeline, May 2018
Table 16: InCarda Therapeutics, Inc. Atrial Fibrillation Pipeline, May 2018
Table 17: Johnson & Johnson Pharmaceutical Atrial Fibrillation Pipeline, May 2018
Table 18: Medtronic, Inc Atrial Fibrillation Pipeline, May 2018
Table 19: Merck & Co Atrial Fibrillation Pipeline, May 2018
Table 20: NeuroSearch Atrial Fibrillation Pipeline, May 2018
Table 21: N-Gene Research Laboratories, Inc. Atrial Fibrillation Pipeline, May 2018
Table 22: Nissan Chemical Industries, Ltd. Atrial Fibrillation Pipeline, May 2018
Table 23: Novartis Pharmaceuticals Atrial Fibrillation Pipeline, May 2018
Table 24: Nyken Atrial Fibrillation Pipeline, May 2018
Table 25: OMEICOS Therapeutics GmbH Atrial Fibrillation Pipeline, May 2018
Table 26: Ono Pharmaceutical Atrial Fibrillation Pipeline, May 2018
Table 27: Pierre Fabre Atrial Fibrillation Pipeline, May 2018
Table 28: Sanofi Atrial Fibrillation Pipeline, May 2018
Table 29: Sanofi; University Hospital Regensburg Atrial Fibrillation Pipeline, May 2018
Table 30: ST Pharm Atrial Fibrillation Pipeline, May 2018
Table 31: Syntex Pharmaceuticals International Atrial Fibrillation Pipeline, May 2018
Table 32: The Geneva Biotech Center SA Atrial Fibrillation Pipeline, May 2018
Table 33: Verseon Atrial Fibrillation Pipeline, May 2018
Table 34: Xention Atrial Fibrillation Pipeline, May 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ActoGeniX
  • BIOCND
  • Clevexel Pharma
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical
  • Enzychem Lifesciences Corporation
  • Galera Therapeutics
  • Genekey Biotech Chengdu Co Ltd
  • GlycoMira Therapeutics
  • Humanetics Corporation
  • Hyloris Pharmaceuticals
  • INC Research Australia Pty Ltd
  • Innovation Pharmaceuticals
  • Intrexon
  • Izun Pharmaceuticals Corporation
  • Monopar Therapeutics
  • Mundipharma International Ltd
  • Novartis Pharmaceuticals
  • Onxeo S.A.
  • Oragenics
  • PolyMedix
  • Santalis Pharmaceuticals
  • SciClone Pharmaceuticals, Inc.
  • Servier Canada Inc
  • Soligenix In
  • Spectrum Pharmaceuticals
  • Spherium Biomed S.L.
  • SRI International
  • Sunny Pharmtech
  • Wellstat Therapeutics Corporation
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll